BUFFALO GROVE, Ill.--(BUSINESS WIRE)--April 3, 2006--Akorn-Strides, LLC, a joint venture company formed between Akorn, Inc. (AMEX:AKN - News) and Strides Arcolab Limited (NSI:STAR), today announced that it has submitted its first Abbreviated New Drug Application (ANDA) with the Office of Generic Drugs. The proposed drug product is a parenteral injectable supporting the antiemetic market, which currently has annual sales of approximately $600 million. Patent protection for the reference-listed drug expires in September 2008.
